MGMT Underexpression

CI-VAR-00004415Explore in graph →CIViC 1255

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Glioblastoma2
MGMT Underexpression	Temozolomide	Predictive	B	Supports Sensitivity Response	3	accepted	EID2899 In this study, patients with low MGMT expression, compared with patients with high MGMT expression, had a significantly higher response rate (55% v 7%, respectively; P = .004) and improved PFS (median… (full text at CIViC) PMID 17442989 · Chinot et al., 2007 · Open in CIViC	civic
MGMT Underexpression	Temozolomide	Predictive	B	Supports Sensitivity Response	3	accepted	EID2903 In 41 glioblastomas treated with temozolomide (TMZ) therapy (MGMT-immunopositive: n = 22, negative: n = 19), both progression free survival and overall survival were significantly better in MGMT-immun… (full text at CIViC) PMID 21331613 · Watanabe et al., 2011 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

High-Grade Glioma, NOS1
MGMT Underexpression	Temozolomide	Predictive	B	Supports Sensitivity Response	3	accepted	EID2901 This study showed that low MGMT mRNA expression was strongly predictive for prolonged time to progression, treatment response, and length of survival in univariate and multivariate models (p<0.0001). … (full text at CIViC) PMID 21365007 · Kreth et al., 2011 · Open in CIViC	civic

Neuroendocrine Tumor1
MGMT Underexpression	Temozolomide	Predictive	B	Supports Sensitivity Response	2	accepted	EID2904 Among those patients who received temozolomide-based therapy in this study, the median progression-free survival for patients whose tumors showed intact MGMT expression was 9.3 months compared with 19… (full text at CIViC) PMID 19118063 · Kulke et al., 2009 · Open in CIViC	civic

Oligodendroglioma1
MGMT Underexpression	Temozolomide	Predictive	B	Supports Sensitivity Response	2	accepted	EID2902 In this study, loss of chromosome 1p and low MGMT protein expression were associated with objective response (P < .003 and P < .04, respectively). However, only 54% of the study group had evaluation o… (full text at CIViC) PMID 16541434 · Levin et al., 2006 · Open in CIViC	civic